Lipoprotein-associated phospholipase A2 and its possible association with COPD development: a case-control study

Area of Science:

• Pulmonary Medicine
• Biochemistry
• Cardiovascular Research

Background:

• Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a known marker for cardiovascular events.
• Its role in Chronic Obstructive Pulmonary Disease (COPD) pathogenesis is not well understood.
• Limited research exists on Lp-PLA2's association with pulmonary conditions like emphysema and small airway dysfunction.

Purpose of the Study:

• To investigate the relationship between serum Lp-PLA2 levels and pulmonary conditions relevant to COPD.
• To examine associations with diffuse pulmonary emphysema, obstructive ventilatory dysfunction, and small airway dysfunction.
• To provide evidence for a potential link between Lp-PLA2 and COPD development.

Main Methods:

• Retrospective analysis of health data from Southwest Hospital Health Management Center (January 2013 - July 2024).
• Inclusion of two case-control populations: Imaging (1056 subjects) and Pulmonary Function (279 subjects).
• Statistical analyses included univariate (t-tests, Chi-square) and multivariate (binary logistic regression) methods to assess Lp-PLA2 levels and pulmonary conditions.

Main Results:

• Serum Lp-PLA2 levels were significantly higher in subjects with diffuse pulmonary emphysema, obstructive ventilatory dysfunction, and small airway dysfunction.
• Multivariate analysis confirmed that higher Lp-PLA2 levels are associated with increased risks of these pulmonary conditions.
• An increasing trend in risk was observed with higher Lp-PLA2 levels, using Lp-PLA2 ≤ 300 U/L as a reference.

Conclusions:

• Lp-PLA2 is independently associated with emphysema, obstructive ventilatory dysfunction, and small airway dysfunction.
• These findings suggest a potential role for Lp-PLA2 in the development of COPD.
• Further validation in larger COPD cohorts is warranted to confirm the association.